Edition:
India

Medivir AB (MVIRb.ST)

MVIRb.ST on Stockholm Stock Exchange

44.00SEK
23 Jan 2018
Change (% chg)

-0.10kr (-0.23%)
Prev Close
44.10kr
Open
43.75kr
Day's High
45.00kr
Day's Low
43.40kr
Volume
43,232
Avg. Vol
72,912
52-wk High
92.00kr
52-wk Low
43.05kr

Chart for

About

Medivir AB is a Sweden-based pharmaceutical company engaged in the research, development and sale of drugs against widespread diseases, with protease and polymerase as its target enzymes. The Company’s research focuses on developing small molecule pharmaceuticals, primarily against infectious diseases caused by viruses. The... (more)

Overall

Beta: 1.15
Market Cap(Mil.): kr1,394.06
Shares Outstanding(Mil.): 19.84
Dividend: --
Yield (%): --

Financials

BRIEF-Medivir: successful completion of pre-clinical safety studies with MIV-818

* SUCCESSFUL COMPLETION OF PRE-CLINICAL SAFETY STUDIES WITH MIV-818, ENABLING START OF PHASE I CLINICAL STUDIES IN 2018 Source text for Eikon: Further company coverage: (Reporting by Stockholm Newsroom)

08 Jan 2018

BRIEF-Medivir announces new cancer project

* Medivir announces new cancer project, Leukotide, derived from its in-house nucleotide platform

08 Nov 2017

BRIEF-Medivir Q3 EBITDA loss widens

* Says ‍net turnover for continuing operations totalled SEK 5.1 million (25.7 m), SEK 5.1 million (13.5 m) of which comprised Q3's royalties​

26 Oct 2017

BRIEF-Medivir receives FDA fast track designation for MIV-711 for treatment of OA

* Medivir receives FDA fast track designation for MIV-711 for the treatment of OA Source text for Eikon: Further company coverage: (Reporting by Stockholm Newsroom)

25 Oct 2017

BRIEF-Medivir says positive top line data from 6-month initial phase IIa study of MIV-711

* Announces positive top line data from MIV-711-201, 6-month initial phase IIa study of MIV-711 in moderate knee osteoarthritis patients Source text for Eikon: Further company coverage:

26 Sep 2017

BRIEF-Medivir: Janssen discontinues development of JNJ-4178 for hepatitis C

* Medivir announces Janssen to discontinue development of JNJ-4178 for hepatitis C

11 Sep 2017

BRIEF-Medivir initiates clinical study of birinapant in combination with keytruda in patients with treatment-refractory solid tumours

* Medivir initiates clinical study of birinapant in combination with keytruda® (pembrolizumab) in patients with treatment-refractory solid tumours Source text for Eikon: Further company coverage: (Reporting by Stockholm Newsroom)

18 Aug 2017

BRIEF-Medivir Q2 EBITDA loss widens

* Says net turnover for continuing operations totalled SEK 9.5 million (36.9 m), SEK 7.7 million (24.2 m) of which comprised Q2's royalties for simeprevir

25 Jul 2017

Earnings vs. Estimates